Since traditional ERα antagonists (tamoxifen) act as GPR30 agonists increasing tumor invasiveness, in the future, co-inhibiting both the ERα and GPR30 receptors may provide a rational therapeutic strategy for the management of estrogen-dependent breast cancers [6, 16]. Here, GPER1 is linked to breast carcinoma.